Please assess the completion status of the following clinical trial:

Trial Title: A Study To Evaluate The Effects And Safety Of Treatment, Treatment Withdrawal, Followed By Re-Treatment With CP-690,550 In Subjects With Moderate To Severe Chronic Plaque Psoriasis

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: QUADRUPLE
- Phase: PHASE3
- Number of Arms: 4.0

Eligibility Criteria:
Inclusion Criteria:~* 18 years or older with diagnosis of plaque-type psoriasis (psoriasis vulgaris) for at least 12 months prior to first dose of study drug;~* Psoriasis Area and Severity Index (PASI) score of 12 or greater, AND Physician's Global Assessment (PGA) score of 3 (moderate) or 4 (severe); Psoriasis covering at least 10% of body surface area;~* No evidence of active or latent or inadequately treated infection with Tuberculosis or other serious infections.~Exclusion Criteria:~* Non-plaque or drug induced forms of psoriasis;~* Cannot discontinue current oral, injectable or topical therapy for psoriasis or cannot discontinue phototherapy (Psoralen Ultraviolet A; Ultraviolet B).~* Any uncontrolled significant medical condition.

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- Active Treatment (10 mg) BID / Placebo BID (Type: EXPERIMENTAL): Continuous active treatment (CP-690,550) for 24 weeks, followed by treatment withdrawal (placebo treatment) for 4-16 weeks, followed by active treatment (CP-690,550) for 16-28 weeks
- Active Treatment (10 mg) BID (Type: EXPERIMENTAL): Continuous active treatment (CP-690,550) for 56 weeks
- Active Treatment (5 mg) BID / Placebo BID (Type: EXPERIMENTAL): Continuous active treatment (CP-690,550) for 24 weeks, followed by treatment withdrawal (placebo treatment) for 4-16 weeks, followed by active treatment (CP-690,550) for 16-28 weeks
- Active Treatment (5 mg) BID (Type: EXPERIMENTAL): Continuous active treatment (CP-690,550) for 56 weeks

Based on this trial design, predict the completion outcome and termination type (if applicable).